Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
Earlier today, the FDA requested additional data to allow a 12-week portion of the Phase 2 PIVOT-HD study…
European Advisory Committee Backs Pfizer/BioNTech’s COVID Shot For Younger Kids
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving Pfizer Inc (NYSE:PFE) and BioNTech SE’s (NASDAQ:BNTX) 3-µg…
FDA Gives Emergency Nod To Novavax’s Adjuvanted COVID-19 Booster Dose
The FDA has granted emergency use authorization to Novavax Inc’s (NASDAQ:NVAX) COVID-19 Vaccine to provide a first booster dose at least six…
RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate
The United States Patent and Trademark Office (USPTO) granted a further method of use patent for RedHill Biopharma Ltd’s (NASDAQ:RDHL) COVID-19 treatment,…
Elevance Health Q3 Earnings Beat Street Estimates, Lifts FY22 Profit Guidance
Elevance Health Inc (NYSE:ELV) reported Q3 FY22 adjusted EPS of $7.53, up 10.9% Y/Y, beating the consensus of $7.16. Operating…
EXCLUSIVE: Issuance Of New Reimbursement-Related Codes Validates Commercial Opportunity For HeartSciences’ Flagship Product
The American Medical Association has issued new industry-first Category III Current Procedural Terminology (CPT) codes for AI assistive algorithmic ECG risk assessment for cardiac dysfunction.
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.
Infant Formula Fiasco Weighs On Abbott’s Q3 Earnings, Still It Raised FY22 EPS Guidance
Abbott Laboratories (NYSE:ABT) has reported Q3 FY22 adjusted EPS of $1.15, down 17.9% Y/Y, better than the consensus of $0.94.…
Jazz Obtains Exclusive Rights To Zymeworks’ Cancer Candidate In Almost $2B Biobuck Deal
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will acquire development and commercialization rights to Zymeworks Inc’s (NASDAQ:ZYME) zanidatamab across all indications in the U.S., Europe, Japan,…
Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason
Ambrx Biopharma Inc (NYSE:AMAM) will prioritize ARX517 as the company’s new lead asset. The company believes ARX517 has the potential to…